DK3658147T3 - Kombination, som omfatter palbociclib og 6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylsyre, og dens anvendelse til behandling af cancer - Google Patents

Kombination, som omfatter palbociclib og 6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylsyre, og dens anvendelse til behandling af cancer Download PDF

Info

Publication number: DK3658147T3
Authority: DK; Denmark
Prior art keywords: annulene; oxyphenyl; fluoropropyl; pyrrolidin; dichlorophenyl
Prior art date: 2017-07-24

Application number

DK18740615.2T

Other languages

English (en)

Inventor

Monsif Bouaboula

Maysoun Shomali

Fangxian Sun

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-07-24

Filing date

2018-07-23

Publication date

2022-01-31

2018-07-23 Application filed by Sanofi Sa filed Critical Sanofi Sa

2022-01-31 Application granted granted Critical

2022-01-31 Publication of DK3658147T3 publication Critical patent/DK3658147T3/da

Links

KISZAGQTIXIVAR-VWLOTQADSA-N 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid Chemical compound ClC1=C(C=CC(=C1)Cl)C1=C(C2=C(CCC1)C=C(C=C2)C(=O)O)C1=CC=C(C=C1)O[C@@H]1CN(CC1)CCCF KISZAGQTIXIVAR-VWLOTQADSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 title 1
229960004390 palbociclib Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK18740615.2T 2017-07-24 2018-07-23 Kombination, som omfatter palbociclib og 6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylsyre, og dens anvendelse til behandling af cancer DK3658147T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762536121P	2017-07-24	2017-07-24
EP17305998.1A EP3434272A1 (en)	2017-07-25	2017-07-25	Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
PCT/EP2018/069901 WO2019020559A1 (en)	2017-07-24	2018-07-23	COMBINATION COMPRISING PALBOCICLIB AND 6- (2,4-DICHLOROPHENYL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-YL] OXYPHENYL] -8,9-DIHYDRO ACID -7H-BENZO [7] ANNULENE-2-CARBOXYLIC AND ITS USE FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number	Publication Date
DK3658147T3 true DK3658147T3 (da)	2022-01-31

Family

ID=59569252

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18740615.2T DK3658147T3 (da)	2017-07-24	2018-07-23	Kombination, som omfatter palbociclib og 6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylsyre, og dens anvendelse til behandling af cancer

Country Status (30)

Country	Link
US (2)	US11260057B2 (da)
EP (2)	EP3434272A1 (da)
JP (1)	JP6741897B1 (da)
KR (1)	KR20200031622A (da)
CN (1)	CN111107851B (da)
AR (1)	AR112284A1 (da)
AU (1)	AU2018308871A1 (da)
BR (1)	BR112020001398A2 (da)
CA (1)	CA3070754A1 (da)
CO (1)	CO2020000240A2 (da)
DK (1)	DK3658147T3 (da)
ES (1)	ES2906279T3 (da)
HR (1)	HRP20212030T1 (da)
HU (1)	HUE057271T2 (da)
IL (1)	IL272166B2 (da)
LT (1)	LT3658147T (da)
MA (1)	MA49673B1 (da)
MX (1)	MX393852B (da)
MY (1)	MY195271A (da)
PH (1)	PH12020500091A1 (da)
PL (1)	PL3658147T3 (da)
PT (1)	PT3658147T (da)
RS (1)	RS62837B1 (da)
RU (1)	RU2764116C2 (da)
SG (1)	SG11202000367RA (da)
SI (1)	SI3658147T1 (da)
TW (1)	TWI768087B (da)
UY (1)	UY37818A (da)
WO (1)	WO2019020559A1 (da)
ZA (1)	ZA202000145B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3434272A1 (en) *	2017-07-25	2019-01-30	Sanofi	Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP7413363B2 (ja) *	2018-09-07	2024-01-15	サノフイ	メチル６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボキシレートの調製方法
BR112021022216A2 (pt) *	2019-05-09	2021-12-28	Sanofi Sa	Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
WO2021063967A1 (en)	2019-10-01	2021-04-08	Sanofi	Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
KR20220113695A (ko) *	2019-12-09	2022-08-16	사노피	7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태
TW202146007A (zh) *	2020-02-27	2021-12-16	法商賽諾菲公司	包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
WO2022084280A1 (en)	2020-10-19	2022-04-28	Sanofi	Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
EP4247363A1 (en) *	2020-11-23	2023-09-27	Sanofi	Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
TW202302084A (zh) *	2021-03-02	2023-01-16	法商賽諾菲公司	以安森司坦和帕博西尼治療乳癌
TW202304425A (zh) *	2021-04-12	2023-02-01	法商賽諾菲公司	包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
KR102815360B1 (ko)	2022-03-03	2025-06-02	인하대학교 산학협력단	암의 예방 또는 치료용 조성물
TW202543650A (zh)	2024-03-08	2025-11-16	美商海爾達醫療運營公司	異雙官能化合物及其在治療疾病中之用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2105655A1 (en)	1991-03-08	1992-09-09	Kent Neuenschwander	Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (de)	1998-07-18	2000-01-20	Schering Ag	Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ES2236056T3 (es)	2001-01-24	2005-07-16	Chiesi Farmaceutici S.P.A.	Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos.
WO2003016270A2 (en)	2001-08-11	2003-02-27	Bristol-Myers Squibb Pharma Company	Selective estrogen receptor modulators
ATE481397T1 (de)	2002-04-24	2010-10-15	Merck Sharp & Dohme	Modulatoren des östrogenrezeptors
CA2512000C (en)	2002-12-26	2011-08-09	Eisai Co., Ltd.	Selective estrogen receptor modulator
WO2006012135A1 (en)	2004-06-24	2006-02-02	Janssen Pharmaceutica, N. V.	Quaternary salt ccr2 antagonists
EP1896391B1 (en)	2005-06-14	2015-08-12	Baylor University	Combretastatin analogs with tubulin binding activity
US8127618B1 (en)	2007-05-18	2012-03-06	Pacesetter, Inc.	Implantable micro-electromechanical system sensor
EP2048126A1 (de)	2007-10-11	2009-04-15	Bayer Schering Pharma AG	Benzocycloheptanderivate als selektiv wirksame Estrogene
DE102010030538A1 (de)	2010-06-25	2011-12-29	Bayer Schering Pharma Aktiengesellschaft	6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en)	2010-09-16	2012-08-29	Aragon Pharmaceuticals Inc	Estrogen receptor modulators and uses thereof
CA2819299A1 (en)	2010-12-24	2012-06-28	Merck Sharp & Dohme B.V.	N-substituted azetidine derivatives
DE102011087987A1 (de)	2011-12-08	2013-06-13	Bayer Intellectual Property Gmbh	6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102584687A (zh)	2011-12-30	2012-07-18	北京赛林泰医药技术有限公司	作为选择性雌激素受体调节剂的乙烯衍生物
CN105658628A (zh)	2011-12-30	2016-06-08	北京赛林泰医药技术有限公司	新型芳基乙烯衍生物及其在选择性雌激素受体调节剂中的应用
KR102529049B1 (ko) *	2013-08-14	2023-05-08	노파르티스 아게	암의 치료를 위한 조합 요법
WO2015028409A1 (de)	2013-08-27	2015-03-05	Bayer Pharma Aktiengesellschaft	6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
KR102785474B1 (ko)	2014-12-18	2025-03-26	에프. 호프만-라 로슈 아게	테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
CN107406424B (zh)	2014-12-18	2020-08-25	豪夫迈·罗氏有限公司	雌激素受体调节剂及其用途
WO2016146591A1 (en) *	2015-03-16	2016-09-22	Astrazeneca Ab	Combination treatment
AR104068A1 (es) *	2015-03-26	2017-06-21	Hoffmann La Roche	Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
JP7019422B2 (ja)	2015-04-29	2022-02-15	ラジウスファーマシューティカルズ，インコーポレイテッド	癌を治療するための方法
CN106924210A (zh) *	2015-12-29	2017-07-07	北京新领先医药科技发展有限公司	一种含有帕布昔利布的胶囊剂及其制备方法
LT3416962T (lt) *	2016-02-15	2021-07-12	Sanofi	6,7-dihidro-5h-benzo[7]anuleno dariniai kaip estrogenų recepptoriaus moduliatoriai
ES3039455T3 (en)	2016-11-17	2025-10-21	Sanofi Sa	Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
EP3434272A1 (en) *	2017-07-25	2019-01-30	Sanofi	Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP7413363B2 (ja)	2018-09-07	2024-01-15	サノフイ	メチル６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボキシレートの調製方法
EP3880202A2 (en) *	2018-11-16	2021-09-22	ArQule, Inc.	Pharmaceutical combination for treatment of cancer

2017
- 2017-07-25 EP EP17305998.1A patent/EP3434272A1/en not_active Ceased
2018
- 2018-07-23 PT PT187406152T patent/PT3658147T/pt unknown
- 2018-07-23 RU RU2020107416A patent/RU2764116C2/ru active
- 2018-07-23 HU HUE18740615A patent/HUE057271T2/hu unknown
- 2018-07-23 IL IL272166A patent/IL272166B2/en unknown
- 2018-07-23 LT LTEPPCT/EP2018/069901T patent/LT3658147T/lt unknown
- 2018-07-23 DK DK18740615.2T patent/DK3658147T3/da active
- 2018-07-23 SG SG11202000367RA patent/SG11202000367RA/en unknown
- 2018-07-23 ES ES18740615T patent/ES2906279T3/es active Active
- 2018-07-23 PL PL18740615T patent/PL3658147T3/pl unknown
- 2018-07-23 KR KR1020207002003A patent/KR20200031622A/ko not_active Ceased
- 2018-07-23 MX MX2020000917A patent/MX393852B/es unknown
- 2018-07-23 JP JP2020503737A patent/JP6741897B1/ja active Active
- 2018-07-23 RS RS20220068A patent/RS62837B1/sr unknown
- 2018-07-23 CN CN201880048755.5A patent/CN111107851B/zh active Active
- 2018-07-23 EP EP18740615.2A patent/EP3658147B1/en active Active
- 2018-07-23 SI SI201830528T patent/SI3658147T1/sl unknown
- 2018-07-23 MY MYPI2020000179A patent/MY195271A/en unknown
- 2018-07-23 CA CA3070754A patent/CA3070754A1/en active Pending
- 2018-07-23 HR HRP20212030TT patent/HRP20212030T1/hr unknown
- 2018-07-23 BR BR112020001398-6A patent/BR112020001398A2/pt not_active Application Discontinuation
- 2018-07-23 WO PCT/EP2018/069901 patent/WO2019020559A1/en not_active Ceased
- 2018-07-23 MA MA49673A patent/MA49673B1/fr unknown
- 2018-07-23 US US16/634,089 patent/US11260057B2/en active Active
- 2018-07-23 AU AU2018308871A patent/AU2018308871A1/en not_active Abandoned
- 2018-07-24 UY UY0001037818A patent/UY37818A/es not_active Application Discontinuation
- 2018-07-24 TW TW107125442A patent/TWI768087B/zh not_active IP Right Cessation
- 2018-07-24 AR ARP180102058 patent/AR112284A1/es not_active Application Discontinuation
2020
- 2020-01-09 ZA ZA2020/00145A patent/ZA202000145B/en unknown
- 2020-01-10 PH PH12020500091A patent/PH12020500091A1/en unknown
- 2020-01-13 CO CONC2020/0000240A patent/CO2020000240A2/es unknown
2022
- 2022-01-19 US US17/579,187 patent/US20220362248A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MY195271A (en)	2023-01-11
EP3658147B1 (en)	2021-11-10
AU2018308871A1 (en)	2020-02-06
CA3070754A1 (en)	2019-01-31
AR112284A1 (es)	2019-10-09
CO2020000240A2 (es)	2020-04-24
PH12020500091A1 (en)	2020-09-14
RS62837B1 (sr)	2022-02-28
JP2020526572A (ja)	2020-08-31
KR20200031622A (ko)	2020-03-24
MA49673A (fr)	2021-03-24
SG11202000367RA (en)	2020-02-27
LT3658147T (lt)	2022-01-10
US20220362248A1 (en)	2022-11-17
RU2020107416A3 (da)	2021-08-25
UY37818A (es)	2020-08-31
RU2020107416A (ru)	2021-08-25
IL272166B2 (en)	2023-04-01
CN111107851B (zh)	2023-05-12
SI3658147T1 (sl)	2022-02-28
ZA202000145B (en)	2021-07-28
JP6741897B1 (ja)	2020-08-19
EP3434272A1 (en)	2019-01-30
IL272166A (en)	2020-03-31
CN111107851A (zh)	2020-05-05
BR112020001398A2 (pt)	2020-07-28
ES2906279T3 (es)	2022-04-18
TWI768087B (zh)	2022-06-21
EP3658147A1 (en)	2020-06-03
RU2764116C2 (ru)	2022-01-13
WO2019020559A1 (en)	2019-01-31
US11260057B2 (en)	2022-03-01
PL3658147T3 (pl)	2022-03-07
US20200171033A1 (en)	2020-06-04
MA49673B1 (fr)	2022-02-28
PT3658147T (pt)	2022-02-02
TW201919612A (zh)	2019-06-01
MX393852B (es)	2025-03-24
IL272166B (en)	2022-12-01
HUE057271T2 (hu)	2022-04-28
HRP20212030T1 (hr)	2022-04-01

Publication	Publication Date	Title
DK3658147T3 (da)	2022-01-31	Kombination, som omfatter palbociclib og 6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylsyre, og dens anvendelse til behandling af cancer
DK3847157T3 (da)	2022-08-08	Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
DK3676297T3 (da)	2023-08-14	Forbindelser, sammensætninger og fremgangsmåder
DK3515523T3 (da)	2021-05-17	Kardiovaskulart hjælpesystem som kvantificerer hjertefunktion og fremmer hjerterestitution
LT3746429T (lt)	2022-05-10	(1-(3-fluor-2-(trifluormetil)izonikotinil)piperidin-4-ono) gamybos būdai
DK3154959T3 (da)	2019-09-30	1-((3s,4r)-4-(3-fluorphenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urinstof som en trka-kinaseinhibitor
DK3341355T3 (da)	2020-10-26	(s)-3-amino-4-(difluormethylenyl)cyclopent-1-en-1-carboxylsyre og tilhørende forbindelser som gaba-aminotransferaseinaktivatorer til behandling af epilepsi, afhængighed og hepatocellulært karcinom
DK3330258T3 (da)	2021-08-16	1, 3, 5-triazinderivat og fremgangsmåde til anvendelse af samme
DK2467364T3 (da)	2014-06-30	Nitrogen-holdige forbindelser og farmaceutiske sammensætninger for behandling af atrial flimren.
IL287805A (en)	2022-01-01	6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene -2-carboxylic for use in metastatic or advanced breast cancer patients
IL272001A (en)	2020-02-27	Custom Titanium Alloy, TI-64, 23plus
DK3271476T3 (da)	2020-06-08	Fremgangsmåder, værktøjer og systemer til vurdering, forebyggelse, styring og behandlingsvalg for type 2-diabetes
DK3653613T5 (da)	2023-01-16	1,3-disubstitueret ketenforbindelse og anvendelse deraf
DK3288825T3 (da)	2019-12-09	Teleskopisk adgangsbro, enhed forsynet hermed og tilhørende fremgangsmåde
DK3592430T3 (da)	2024-09-16	Antimikrobielle forbindelser, sammensætninger og anvendelser heraf
EP4003454A4 (en)	2023-07-26	MEDICAL DEPARTMENT, COMPONENTS AND IDENTIFICATION SYSTEM
IT201700117210A1 (it)	2019-04-17	Fungicida biologico
DK3456712T3 (da)	2022-05-30	Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
HUE048750T2 (hu)	2020-08-28	(R)-3-((3S,4S)-3-fluor-4-(4-hidroxifenil)piperidin-l-il)-l-(4-metilbenzil)pirrolodin-2-on és prodrugjai pszichiátriai rendellenességek kezelésére
DK3953348T3 (da)	2025-03-17	Forbindelser, sammensætninger og fremgangsmåder
EP3982737C0 (fr)	2023-10-11	Bloc de levain vivant découpable
LT3408260T (lt)	2021-07-26	Kristalinė (2s,4r)-5-(5'-chlor-2-fluor-[1,1'-bifenil]-4-il)-2-(etoksimetil)-4-(3-hidroksi-izoksazol-5-karboksamido)-2-metilpentanoinė rūgštis ir jos panaudojimai
DK3288949T3 (da)	2020-01-13	Tetrahydrofuran-fusionerede aminohydrothiazin-derivater, som er anvendelige inden for behandling af Alzheimers sygdom
EP3233824A4 (en)	2018-05-30	(s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
DK3579874T3 (da)	2021-10-11	1-(4-amino-5-brom-6-(1h-pyrazol-1-yl)pyrimidin-2-yl)-1h-pyrazol-4-ol og anvendelse deraf til behandling af cancer